PCV63 COST OF CARDIOVASCULAR DISEASE IN KOREA: INCIDENCE-BASED APPROACH  by Lee, YS et al.
A324 Paris Abstracts
patients were identiﬁed having: q2 claims for primary pulmonary hypertension (ICD-
9-CM: 416.0); no claims associated with left heart disease, lung diseases, chronic 
thromboembolic pulmonary hypertension, or miscellaneous pulmonary hypertension 
within 12 months prior or 1 month after the initial pulmonary hypertension claim 
(index date); ages 18–64. Patients with PAH were matched demographically to con-
trols without pulmonary hypertension. All were required to have continuous health 
coverage for six months before (baseline) and one month after the index date. A vari-
able study period was used to follow patients as long as continuously eligible; mean 
follow-up was 24.8 months. Chi-squared tests were used to compare baseline comor-
bidities. Wilcoxon rank-sum tests were used for univariate comparisons of direct 
(medical and pharmaceutical) patient-month costs to insurers for PAH patients vs. 
controls. RESULTS: Average age for patients with PAH was 52.2 years, and 54.7% 
were women. Compared with controls, PAH patients had signiﬁcantly higher baseline 
comorbidity rates (e.g., essential hypertension, diabetes, congestive heart failure, and 
mental health disorders) and a higher Charlson Comorbidity Index. Mean (median) 
direct patient-month costs were $1775 ($503) for PAH patients and $441 ($92) for 
controls (p  0.0001), yielding excess costs of $1334 ($411). Inpatient services 
accounted for 43%, outpatient services for 40%, and drug costs for 15% of PAH 
direct patient-month costs. Circulatory/respiratory system-related patient-month costs 
were $583 ($144) among PAH patients and $113 ($8) among controls (p  0.0001), 
yielding excess costs of $470 ($185). CONCLUSIONS: Patients with PAH had sub-
stantially higher costs than matched controls. Circulatory/respiratory system-related 
costs represented 33% of the costs of patients with PAH and 35% of the difference 
in costs between patients with PAH and controls.
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OBJECTIVES: This study was performed to investigate incidence-based medical cost 
of cardiovascular diseases(CVD) in Korea. METHODS: Cohort including 605 CVD 
patients from 10 hospitals were used to estimate the cost up to the second year from 
the ﬁrst occurrence of CVD. Study hospitals were selected from the hospitals who 
implemented more than 60 Percutaneous Coronary Intervention (PCI) in 2006 and 
were willing to provide individual patient cost data. Only 10 among 84 eligible hos-
pitals agreed to provide cost data. Average annual cost of the patients who were 
diagnosed as Myocardiac Infarction (I21^I22), angina(I20) or heart failure(I50) were 
calculated using computerized database of each hospitals. Cost included insurance-
covered cost as well as out-of-pocket medical payment during two years. Indirect cost 
and non-medical cost were not investigated in this study. We got necessary IRB 
approval to get this data. RESULTS: The total annual medical cost of CVD patient 
were calculated as 11,860,445 Won for ‘acute myocardial infarction(I21)’, 9,517,898 
Won for ‘subsequent myocardial infarction(I22)’, 6,496,871 Won for ‘heart 
failure(I50)’, and 5,170,170 Won in ‘angina pectoris(I20)’, respectively. Inpatient cost 
accounted from 89.1% to 97.0% depending on diseases. Cost difference according to 
referral level or region were not statistically signiﬁcant. The CVD cost in the 1st year 
of ﬁrst event (7,058,537 Won) were signiﬁcantly higher than that of 1st year of recur-
rent event (4,789,785 Won) and that of 2nd year of CVD diagnosis (1,325,601 Won) 
(p  0.000). CONCLUSIONS: Estimated CVD cost was a little bit higher than that 
of previous studies which was conducted in Korea. This is mainly because we used 
real hospital charge data while previous studies depended on insurance claim data. 
They did not covered non-reimbursed cost. The results should cautiously be inter-
preted, however, to generalize to other hospitals since many candidate hospitals 
refused to be included in this study.
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OBJECTIVES: Evaluate the short and long-term economic burden of acute ischemic 
stroke (AIS)/transient ischemic attack (TIA) in a real-world setting. METHODS: 
Patients in PharMetrics®, a large claims database of U.S managed care plans, with an 
initial hospitalization for AIS or TIA (inpatient ICD-9 codes; 433.x1, 434.01, 434.11, 
434.91, 436.xx or 435.x) between 1995 and 2008 were included in the study. Medical 
care encounters, resource utilization, and hospital charges were extracted from health 
care claims. Mean total charges post-index stroke as well as charges for initial AIS/TIA 
hospitalization and re-hospitalizations for stroke, acute coronary syndrome (ACS), 
and peripheral artery disease (PAD) were computed for all patients. Multivariate 
models identiﬁed drivers of higher charges. RESULTS: A total of 163,493 AIS/TIA 
patients were identiﬁed [AIS: 110,105 (67.3%), TIA: 53,388 (32.7%)]. In univariate 
analyses, the mean initial hospitalization charge was $16,867 for TIA and $25,414 
for AIS hospitalizations. While the greatest charges were accrued in the year post-index 
stroke ($57,937), patients experienced charges of at least $22,000 each year following 
initial hospitalization for 5 years. Among AIS/TIA patients, 57,142 (35%), 27,736 
(17%), and 8,210 (5%) experienced a subsequent hospitalization for AIS, TIA, and 
hemorrhagic stroke with associated average hospitalization charges of $7,967, $8,649, 
and $16,611, respectively. Re-hospitalization for PAD and ACS occurred for 24,145 
patients (14.8%), with average costs of $12,293 and $24,580, respectively. Multivari-
ate analyses controlling for key covariates demonstrated that cardiac arrhythmia/atrial 
ﬁbrillation, acute myocardial infarction, and hypertension were strongly associated 
with increased hospitalization charges for initial AIS/TIA hospitalization (p  0.0001). 
CONCLUSIONS: The economic burden of AIS/TIA is substantial; the costs are sig-
niﬁcant and continue over at least a ﬁve year period post AIS/TIA event. For patients 
with an initial AIS/TIA hospitalization, it is important to consider the economic 
implications of preventing hospitalizations for recurrent stroke as well as other ath-
erothrombotic and cardioembolic events.
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OBJECTIVES: Atherothrombosis is a systemic disease associated with a high risk of 
cardiovascular morbidity and mortality, which represents a huge economic burden. 
Peripheral Arterial Disease (PAD) puts patients at a higher risk of atherothrombotic 
events. The aim of this study was to examine the economic impact of PAD as an added 
risk factor in patients with coronary artery disease (CAD) and cerebrovascular disease 
(CVD) using cumulative 2-year follow-up data from REACH patients from Spain. 
METHODS: The REACH Registry is an international registry of 67,888 patients at 
risk of atherothrombosis due to established CAD, CVD and/or PAD, or q3 risk factors. 
Cumulative 2-year rates of cardiovascular (CV) events for CV death, myocardial inf-
arction (MI) and stroke along with their associated direct (medication and hospitaliza-
tion) and indirect costs (productivity losses) were compared across patient subgroups 
(CAD, CVD, and/or PAD) in 2050 REACH patients. RESULTS: The 2-year CV event 
rates of the composite CV-death/MI/stroke/CV hospitalization for patients with CAD 
and CVD were 21.3% and 16.0%, respectively. Presence of symptomatic PAD as an 
additional risk factor increased these event rates to 30.6% and 23.3%, respectively. 
Cumulative 2-year vascular-related total costs were a4.747 for CAD and a3201 for 
CVD. These costs increased to a6205 and a5978, respectively, for patients with an 
additional history of symptomatic PAD. This increase in cost was due to the roughly 
doubling of hospitalization costs resulting from the observed higher rates of major 
cardiovascular events and peripheral vascular interventions and procedures (peripheral 
angioplasty/stenting, peripheral bypass graft, lower limb amputation) in patients with 
symptomatic PAD as an additional risk factor. CONCLUSIONS: CV events and hos-
pitalization rates, and associated costs, tend to increase with the number of affected 
vascular beds; especially when PAD is also present in patients with CAD or CVD, 
compared to patients with CAD and CVD only.
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OBJECTIVES: In the ATHENA trial, dronedarone signiﬁcantly reduced the risk of 
hospitalizations for cardiovascular (CV) causes or death in patients with atrial ﬁbril-
lation (AF) and/or atrial ﬂutter (AFL). We evaluated the costs of ATHENA-like trial 
endpoints among a cohort of US AF/AFL patients without heart failure (HF) who had 
employer-sponsored Medicare supplemental insurance. METHODS: This retrospec-
tive cohort study used claims data from 2004 to 2007 from the MarketScan® databases 
from Thomson Reuters. Patients were included if they were aged q70 years, had evi-
dence of non-transient AF/AFL in 2005 (index diagnosis) and q1 CV disease/risk 
factors but no HF during the 12 months pre-index diagnosis, and had q12 months’ 
continuous enrollment following the ﬁrst observed hospitalization (index hospitaliza-
tion) post-index diagnosis. Direct health care costs were calculated for 12 months 
following the index hospitalization. RESULTS: Overall, 10,200 AF/AFL patients 
(mean age 79.5 years; 46.8% men) were included; 38.4% had q1 rehospitalization 
for any cause (post index hospitalization). Hospitalization for CV causes occurred in 
51.3% of all patients; with a total of 6,436 CV hospitalizations (mean cost $10,908/
hospitalization). CV inpatient deaths occurred in 2.6% of patients (mean cost 
$18,565/death). The most frequent cause of CV hospitalizations was AF/other supra-
ventricular rhythm disorders; the most frequent cause of death during a CV hospital-
ization was gastrointestinal/intracranial bleeding. Acute/subacute endocarditis was the 
most expensive cause of a CV hospitalization (mean $81,121/event) and CV surgery 
was the most expensive cause of CV inpatient death (mean $29,873/death). Non-fatal 
cardiac arrest was the least expensive cause of a CV hospitalization ($1961/event) and 
ventricular arrhythmia the least expensive cause of inpatient death during a CV hos-
pitalization ($6146/death). CONCLUSIONS: The costs of ATHENA-like trial end-
points (CV hospitalizations and inpatient death) are high in US AF/AFL patients 
without HF. Dronedarone may reduce CV hospitalizations and mortality in similar 
patients and potentially reduce associated costs.
